Ideaya Biosciences Inc

+0.20 (+2.04%)
Products, Strategic Combinations

Ideaya Announces Development Candidate Nomination Of A Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With Gsk

Published: 06/28/2022 10:13 GMT
Ideaya Biosciences Inc (IDYA) - Ideaya Announces Development Candidate Nomination of a Potential First-in-class Pol Theta Helicase Inhibitor in Collaboration With Gsk.
Ideaya - on Potential Commercialization, Co Eligible to Receive Up to $475 Million of Commercial Milestones & Tiered Royalties on Global Net Sales by Gsk.
Ideaya-observed Complete Responses in Preclinical Combination Studies of Pol Theta Helicase Dc With Niraparib in Multiple in Vivo Pdx & Cdx Hrd Models.
Ideaya - Co and Gsk Are Targeting Ind Submission for Pol Theta Helicase Dc, Subject to Completion of Ongoing Preclinical and Ind-enabling Studies.